The increasing burden of depression by Lépine, Jean-Pierre & Briley, Mike
© 2011 Lépine and Briley, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Neuropsychiatric Disease and Treatment 2011:7(Suppl 1)3–7
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
3
SHORT REPORT
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/NDT.S19617
The increasing burden of depression
Jean-Pierre Lépine1
Mike Briley2
1Hôpital Lariboisière Fernand Widal, 
Assistance Publique Hôpitaux de Paris 
Unité INSERM 705 CNRS UMR 
8206, Université Paris Diderot, Paris, 
France; 2NeuroBiz Consulting and 
Communication, Castres, France
Correspondence: Jean-Pierre Lépine 
Hôpital Lariboisière Fernand Widal, 
Assistance Publique Hôpitaux de Paris, 
200, rue du Faubourg Saint-Denis 
75010 Paris, France 
Tel +33 1 40 05 48 69 
Fax +33 1 40 05 49 33 
Email jean-pierre.lepine@lrb.ap-hop-paris.fr
Abstract: Recent epidemiological surveys conducted in general populations have found that 
the lifetime prevalence of depression is in the range of 10% to 15%. Mood disorders, as defined 
by the World Mental Health and the Diagnostic and Statistical Manual of Mental Disorders, 
4th edition, have a 12-month prevalence which varies from 3% in Japan to over 9% in the US. 
A recent American survey found the prevalence of current depression to be 9% and the rate 
of current major depression to be 3.4%. All studies of depressive disorders have stressed the 
importance of the mortality and morbidity associated with depression. The mortality risk for 
suicide in depressed patients is more than 20-fold greater than in the general population. Recent 
studies have also shown the importance of depression as a risk factor for cardiovascular death. 
The risk of cardiac mortality after an initial myocardial infarction is greater in patients with 
depression and related to the severity of the depressive episode. Greater severity of depressive 
symptoms has been found to be associated with significantly higher risk of all-cause mortality 
including cardiovascular death and stroke. In addition to mortality, functional impairment and 
disability associated with depression have been consistently reported. Depression increases 
the risk of decreased workplace productivity and absenteeism resulting in lowered income or 
unemployment. Absenteeism and presenteeism (being physically present at work but function-
ing suboptimally) have been estimated to result in a loss of $36.6 billion per year in the US. 
Worldwide projections by the World Health Organization for the year 2030 identify unipolar 
major depression as the leading cause of disease burden. This article is a brief overview of how 
depression affects the quality of life of the subject and is also a huge burden for both the family 
of the depressed patient and for society at large.
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Introduction
Depression is a common disorder, affecting over 120 million people worldwide. Recent 
epidemiological surveys conducted in general populations have found that the lifetime 
prevalence of depression is in the range of 10% to 15%. Mood disorders as defined 
by the World Mental Health (WMH) and the Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition (DSM-IV) have a 12-month prevalence which varies 
from 3% in Japan to over 9% in the US.1 Although disorder severity correlates with 
the probability of treatment in almost all countries, 35.5% to 50.3% of serious cases 
in developed countries and 76.3% to 85.4% in less-developed countries received no 
treatment in the 12 months preceding the interview.
The US Centers for Disease Control (CDC) 2006 and 2008 surveys of 235,067 
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found the rate of current depression (using the Patient Health 
Questionaire-8) to be 9% and the rate of those with a current 
diagnosis of major depression (DSM-IV criteria) to be 3.4%.2 
The high female:male sex ratio in the prevalence of depres-
sion, especially during the reproductive years, is one of the 
most replicated findings in epidemiology.3 French data from 
the European Study of the Epidemiology of Mental disorders 
(ESEMeD) supported this finding – that globally, approxi-
mately twice as many women suffered from depression as 
men. This distribution was true across all age groups with 
the single exception of the 18 to 24 years age group where 
there was approximate parity between the sexes (Lépine 
unpublished data).
A reduction of the classical female:male odds ratio for 
major depressive disorder was also found in the younger age 
group (18–34) compared with other age groups in a recent 
analysis of worldwide surveys.4 These authors suggest that 
the relative decrease in the prevalence of depression in 
women may be the result of the increase in female oppor-
tunities in education, employment, birth control, and other 
factors increasing gender equality. It will be interesting to 
see if the more equilibrated female:male sex ratio will persist 
as this younger cohort ages.
Burden of depression
Even when successfully treated and remission is achieved, 
depressive disorders still impose a considerable burden on 
the patient. Remission is rarely accompanied by a total dis-
appearance of all symptoms. Residual symptoms, especially 
cognitive impairment or social dysfunction, can continue to 
reduce performance and cause considerable distress. The 
ever-present risk of relapse and recurrence also weighs heav-
ily generally reducing the quality of life.
A recent review5 reported that the rate of recurrence 
of major depressive disorder treated in specialized mental 
health settings was very high (60% after 5 years, 67% after 
10 years, and 85% after 15 years) but was significantly 
lower in the primary care population (35% after 15 years). 
As found in other studies6 the number of previous episodes 
and subclinical residual symptoms were the most important 
predictors of relapse.
Increased mortality risk
The burden of depressive disorder extends far beyond the 
disorder itself (Table 1) influencing the mortality risk of the 
patient. The standardized mortality ratio (SMR) for suicide 
in patients with unipolar depression is 20.9 in men and 27.0 
in women.7 In other terms, depressed men and women are 
Table 1 Burden of depression
Classical burden
• Residual symptoms
• Cognitive impairment
• Relapse and recurrence
• Decreased quality of life
Mortality burden
• Suicide
• Cardio- and cerebrovascular
Disability burden
• Psychosocial
• Work days lost
Family burden
Economic burden
Table 2 Affective disorders and suicide risk
Lifetime prevalence of suicide in patients
• Hospitalized at some time in their life for suicidality 8.6%
• Affective disorders inpatients 4.0%
• Affective disorders outpatients 2.2%
• No affective illness ,0.5%
Compiled from data in reference 8.
20.9 and 27 times, respectively, more likely to commit suicide 
than the general population. A 2000 meta-analysis of deaths 
by suicide concluded that there was a hierarchy in the lifetime 
prevalence of suicide among patients with affective disorders 
(Table 2), with patients hospitalized for attempted suicide 
having an almost 20-fold greater prevalence than subjects 
who had never had any affective illness.8
The risk of cardiac mortality after an initial myocardial 
infarction is greater in patients with depression and this risk 
is related to the severity of the depressive episode. A study 
of 896 patients hospitalized for myocardial infarction found 
a direct relationship between the severity of the depressive 
symptoms as measured by the Beck Depression Inventory 
Score at hospitalization and the risk of cardiac death over 
the following 5 years.9
Similarly, a meta-analysis of 20 studies10 has shown that 
clinical depression is a significant risk factor for mortal-
ity in patients with coronary heart disease both short-term 
(3–6 months; adjusted odds ratio 2.07) and long-term 
(6–24 months; adjusted odds ratio 2.61).
Another study evaluated long-term mortality risks mea-
sured at middle age among 12,866 men with a high risk for 
coronary heart disease. Greater depressive symptoms were 
found to be associated with significantly higher risk of all-
cause mortality and a higher risk of cardiovascular death and, 
more specifically, stroke mortality.11Neuropsychiatric Disease and Treatment 2011:7(Suppl 1) submit your manuscript | www.dovepress.com
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Even the risk of death by all causes is increased in 
depressed patients who are twice as likely to die prematurely 
compared with the general population (SMR 1.9 men; 2.1 
women).7
A study of a cohort of 5276 community-dwelling elderly 
men (aged 68–88 years) in Perth, Australia investigated the 
883 deaths (from all causes) occurring during the 6-year 
follow-up period.12 The adjusted mortality hazard (MH) of 
men with clinical depression was nearly twice (MH = 1.98) 
that of the total cohort. Furthermore MH increased with the 
severity of depression from 1.39 for borderline depression 
to 3.32 for severe depression. The use of antidepressants did 
not reduce the mortality risk.
Further evidence of increased all cause mortality risk 
in psychiatric patients has come from study of the GAZEL 
cohort.13 The French GAZEL cohort (n = 19,962 aged 35–50) 
used data from the medical department of the French utility 
company Electricité de France-Gaz de France. Physician-
certified sickness absence records (.7 days) were extracted 
from administrative files (1990–1992) and were linked to 
mortality data from France’s national registry of mortal-
ity (1993–2008, mean follow-up: 15.5 years). Compared 
with workers with no sickness absence, those absent due 
to psychiatric disorders had an increased risk of death from 
suicide, from cardiovascular disease, and from smoking-
related cancer (Table 3).
Functional burden
An analysis of data from the National Comorbidity Survey 
Replication, a US nationally representative household survey,14 
found that overall impairment was significantly higher for 
mental disorders than for chronic medical disorders. Severe 
functional impairment was reported by 42% persons with 
mental disorders and 24% with chronic medical disorders. 
Treatment, however, was provided for a significantly lower 
proportion of mental (21.4%) than chronic medical (58.2%) 
disorders. Whereas chronic medical disorders are most likely 
to be associated with impairment in domains of work and home 
functioning, mental disorders are most commonly associated 
with problems of social interaction and close relationships.
Psychosocial disability is related to depressive symp-
tom severity during the long-term course of unipolar major 
depression (MD).15 In a study of 371 patients with unipolar 
MD in the National Institute of Mental Health Collab-
orative Depression Study, monthly ratings of impairment 
in life functions and social relationships over an average 
of 10 years’ follow-up were found to be associated with a 
degree of depressive symptom severity. Significant increases 
in disability occurred with each stepwise increment in 
depressive symptom severity (asymptomatic . subthreshold 
depressive symptoms . symptoms at the minor depression/
dysthymia level . symptoms at the MD level).
Depression is also associated with decreased productiv-
ity in the workplace and an increased risk of absenteeism 
from work.16 One study followed 2334 participants, who were 
employed full or part time and who reported an annual family 
income of at least US$25,000, over a 5 years. The presence 
of clinical depression, defined as a score $16 on the CES 
depression scale, was related to increased unemployment and 
decreased annual salary.17 Over the 5-year follow-up period 
33% of depressed participants reported new unemployment 
compared with 21% of nondepressed participants. After cor-
rection for confounding factors the association remained highly 
significant (odds ratio, 1.6 P = 0.001); 17% of participants with 
depressive symptoms and 7% of participants without substan-
tial depressive symptoms at baseline reported that their family 
income had decreased below US$25,000 5 years later. This 
association remained significant after adjusting for potential 
confounding variables (odds ratio, 1.9 P , 0.001).
The National Comorbidity Survey Replication18 found 
that taking into account both absenteeism and presenteeism 
(being physically present at work but functioning subopti-
mally) an average of over 27 workdays per year were lost per 
depressed employee representing an annual individual loss 
of US$4400. At a national level, this translates into a loss of 
US$36.6 billion per year in the US.
Family burden
Problems of social dysfunction,19 decreased income resulting 
from workplace absenteeism, underperformance or unemploy-
ment (see above) are a burden for the patient and the patient’s 
partner and family. At a time when the depressed patient is at 
greatest need of social support, depression tends to disrupt 
family stability frequently leading to separation or divorce. 
The link between depression and divorce can be bi-directional. 
A study using the longitudinal component of the Canadian 
Table 3 Sickness absence due to psychiatric disorder and mortality
HR Adjusted HR
Suicide 6.01 5.13
Cardiovascular disease 1.84 1.59
Smoking-related cancer 1.65 1.31
Notes:  HR  = hazard ratio over a mean of 15.5 years in workers with absence 
(.7 days) due to a psychiatric disorder compared with workers with no sickness 
absence. Adjusted HR, adjusted for marital status, tobacco smoking, and alcohol use. 
Based on data from the French GAZEL cohort (n = 19,962 aged 35–50 years) 
and the French national registry of mortality (1993–2008). Compiled from data in 
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National Population Health Survey (1994/1995 through 
2004/2005) examined the relationship between the dissolu-
tion of a marital or cohabiting relationship and subsequent 
depression among Canadians aged 20 to 64 years.20 For both 
sexes, dissolution of a marriage or cohabiting relationship was 
associated with higher odds of a new episode of depression, 
compared with those who remained with a spouse or partner 
over the 2-year period following the depressive episode. Mari-
tal dissolution was more strongly associated with depression 
among men than among women.
Depression in women during pregnancy is common. Preva-
lence rates have been reported to be 7.4%, 12.8%, and 12.0% 
for the first, second, and third trimesters, respectively.21,22 Other 
studies have shown that 10% to 16% of pregnant women fulfill 
the diagnostic criteria for MD, and even more women experience 
subsyndromal depressive symptoms.23 Some of the numerous 
risks of maternal depression for the fetus, the newborn baby, and 
its subsequent development are summarized in Table 4.
DALY measurements and predictions
DALY, disability adjusted life-years, is the sum of life-years lost 
due to premature death and years lived with disability adjusted 
for severity.23 It integrates the notions of individual mortality 
and disability with global disease prevalence. Using the DALY, 
unipolar MD was classed in 1990, as the fourth leading burden 
of disease or injury cause worldwide for both sexes, behind 
lower respiratory infections, diarrheal diseases, and perinatal 
disorders.24 By 2004 it had moved up to third place and World 
Health Organization projections25 estimate that it will be the 
leading cause of disease burden worldwide by 2030.
Conclusion
Depression has a high prevalence worldwide in both developed 
and developing countries. In addition to the profound effects 
on the quality of life of the patient, depression has a major 
impact on mortality risk by suicide, and on cardiovascular 
and other diseases as well as death by all causes. Depression 
impairs cognitive and social functioning leading to decreased 
performance in the workplace and elsewhere. This dysfunc-
tion has considerable economic impact on the individual, his 
or her family, his or her employer, and on society at large. 
Depression, especially maternal depression, affects the health 
and development of the baby with possible long-term conse-
quences for the mental health of future generations.
In view of the profound and widespread burden caused 
by depression it is hardly surprising that analysis of DALYs 
puts depression among the leading causes of burden of dis-
eases worldwide. As the infectious diseases, especially in 
developing countries, are progressively controlled, depression 
is predicted to become the major health burden worldwide. 
Thus prevention and treatment of depression must be seen as 
a priority medical challenge for the 21st century.
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